References
- Lim DJ, Birck H. Ultrastructural pathology of the middle ear mucosa in serous otitis media. Ann Otol Rhinol Laryngol 1971; 80: 838–53.
- Nell MJ, Grote JJ. Structural changes in the rat middle ear mucosa due to endotoxin and eustachian tube obstruction. Eur Arch Otorhinolaryngol 1999; 256: 167–72.
- Rhee CK, Park YS, Long SA, Jung TT, Davamony D. Effects of platelet activating factor on vascular perme-ability of the middle ear mucosa. Ann Otol Rhinol Laryngol 1997; 106: 604 7.
- Goldie P, Jung TT, Hellstrom S. Arachidonic acid metabolites in experimental otitis media and effects of anti-inflammatory drugs. Ann Otol Rhinol Laryngol 1993; 102: 954–60.
- Boisvert P, Wasserman SI, Schiff M, Ryan AF. Hista-mine-induced middle ear effusion and mucosal histo-pathology in the guinea pig. Ann Otol Rhinol Laryngol 1985; 94: 212–6.
- Jung HH, Kim MW, Lee JH, et al. Expression of vascular endothelial growth factor in otitis media. Acta Otolaryngol (Stockh) 1999; 119: 801–8.
- Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular perme�ability factor. Cancer Res 1990; 50: 1774–8.
- Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470–8.
- Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306 9.
- de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989–91.
- Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579–86.
- Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors [Review]. FASEB J 1999; 13: 9–22.
- Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 1998; 273: 31273–82.
- Keyt BA, Nguyen HV, Berleau LT, et al. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed muta�genesis. J Biol Chem 1996; 271: 5638–46.
- Weninger W, Partanen TA, Breiteneder-Geleff S, et al. Expression of vascular endothelial growth factor recep-tor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 1999; 79: 243 51.
- Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62–6.
- Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66–70.
- Gille H, Kowalski J, Li B, et al. Analysis of biological effects and signaling properties of Flt-1 and KDR: a reassessment using novel highly receptor-specific VEGF mutants. J Biol Chem 2001; 276: 3222–30.
- Stacker SA, Vitali A, Caesar C, et al. A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability. J Biol Chem 1999; 274: 34884 92.
- Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470–8.
- Senger DR, Galli S J, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular perme-ability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983 5.
- Dvorak HF, Orenstein NS, Carvalho AC, et al. Induc�tion of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol 1979; 122: 166 74.
- Kaipainen A, Korhonen J, Mustonen T, et al. Expres�sion of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during develop�ment. Proc Natl Acad Sci U S A 1995; 92: 3566 70.
- Kukk E, Lymboussaki A, Taira S, et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular devel�opment. Development 1996; 122: 3829–37.